Muzzy Family Endowed Fellowship in Molecular Imaging and Therapy
- Goals & Objectives
- Program Details
- Faculty
Goals and Objectives
Clinical Experience & Training
Fellows in the Hoag Molecular Imaging and Therapy Program receive comprehensive clinical experience in molecular imaging and therapy, play a significant role in diagnostic consultation and are actively involved in regular triage of patients to ensure that the appropriate study is performed.
Collaborative Education & Teamwork
Faculty members are firmly committed to extensive elbow-to-elbow education in the reading room and Molecular Imaging and Therapy clinic and work collaboratively with a team of physicians, nurses, nuclear technologists and physicists.
Advanced Imaging Training
Graduates of the program will gain expertise of molecular imaging and therapy through experience with > 1,500 PET/CT and PET/MR examinations and administration of > 300 radionuclide therapies. Fellows will also master clinical trial execution, including the completion, presentation, and publication of a mentored investigation.
Certification & Career Advancement
Upon completion of the program, the Fellow will be eligible for both the American Board of Nuclear Medicine and the American Board of Radiology-Nuclear Radiology certifying exams. It is expected the Fellow will far exceed the requirements for these exams. Graduates of the program will be well poised in to obtain an academic or community position as a Radiologist and/or Molecular Imaging and Therapy specialist.
Program Details
- This one (1) year program will provide a broad clinical experience in all aspects of molecular imaging and therapy, including:
- FDA-approved PET radiotracers (FDG, 68Ga-Dotatate, 64Cu-Dotatate, Pylarify, Cerianna, Axumin)
- Investigational PET radiotracers (targeting PSMA, ER, FAP, CD8, CD38, Amyloid, Tau, and others)
- FDA-approved radionuclide therapies (Pluvicto, Lutathera, Radioiodine)
- Investigational radionuclide therapies (targeting PSMA, FAP, SSTR, and others, including 225Ac alpha therapies)
- PET/CT and PET/MR
- General nuclear medicine
- Basic principles of radiotracers, radiopharmacy, and radiation safety.
- The program director ensures rotation responsibilities do not detract from a fellow’s overall educational experience. The allocation of fellowship time will be scheduled in advance and in collaboration with the fellow.
- 40% Clinical service for PET/CT, PET/MR
- 40% Clinical service in the Molecular Imaging & Therapy clinic
- 20% Clinical investigation. Each fellow will be mentored on an original research project with the goal of national/international presentation and publication.
Rotations are conducted primarily at the Molecular Imaging and Therapy clinic in Irvine, California with the Radiology Department of Hoag Hospital in Newport Beach, California as a secondary site. Fellows are expected to report to work Monday-Friday, except approved holidays. There will be no call responsibilities.
- Fellows will have approximately 20% of their time allocated towards a dedicated and supervised research project. Each fellow will be mentored in an original research project with the goal of national/international presentation and publication.
- Requirement: Mastery of clinical trial execution, including the completion, presentation and publication of a mentored investigation.
- Current Clinical Trials at the Hoag Molecular Imaging and Therapy clinic include:
- 3 PET/CT scanners: Biograph 64 Vision 450; Biograph mCT Flow; Biograph Truepoint
- 1 PET/MR Scanner: Biograph mMR
- 3 SPECT/CT scanners: all Symbia T
- 5 additional nuclear cameras
- Full Molecular Imaging and Therapy clinic with 3 lead lined therapy rooms, radiopharmacy, and office space
Clinical trials with novel Molecular Imaging and Therapy Agents:
Prostate Cancer
- 177Lu-PNT2002 therapy for metastatic prostate cancer(SPLASH)
- 177Lu-PNT2002 expanded access program for metastatic prostate cancer
- 177Lu-PSMA I&T therapy for metastatic prostate cancer (ECLIPSE)
- 131I-PSMA therapy for metastatic prostate cancer (ARROW)
- 225Ac-PSMA I&T therapy metastatic prostate cancer
- 64Cu-PSMA I&T for newly diagnosed, high risk prostate cancer
- 64Cu-PSMA I&T for biochemically recurrent prostate cancer
- 18F-Piflufolastat for newly diagnosed, favorable intermediate prostate cancer imaging (MIRROR)
- Phase 1 trial of 61Cu-PSMA for imaging prostate cancer
Clinical trials with novel Molecular Imaging and Therapy Agents:
Breast Cancer
- Estrogen Receptor (ER)-targeted imaging with FES for newly diagnosed and recurrence breast cancer
- Dotatate PET for SSTR2-targeted PET imaging of ER+ metastatic breast cancer
- 225Ac-Dotatate therapy for metastatic breast cancer
- 89Zr-CD8 immunoPET for prediction of immunotherapy response
Clinical trials with novel Molecular Imaging and Therapy Agents:
Neuroendocrine Tumors
- 225Ac-Dotatate Therapy for neuroendocrine tumors (ACTION-1)
Myeloma
- CD38-targeted immunoPET for myeloma
Solid Tumors
- 111In-FPI-2058 225Ac-FPI-2059 for neurotensin receptor targeted imaging and therapy of multiple solid tumors
- Weekly didactics covering FDG PET/CT of all organ systems and specialized lectures covering each targeted imaging and therapy application.
- Fellows participate regularly in at least one of the 16 organ specific Tumor Boards at the Hoag Family Cancer Institute.
- Fellows participate in a variety of multidisciplinary conferences where input from numerous subspecialties determines the optimal course of therapies for the patient.
- Visiting Professorships: Through the Hoag Foundation Visiting Professorship Fund, nationally acclaimed physicians are brought to Hoag as guest speakers. Fellows are encouraged to attend these lectures.
- 3 PET/CT scanners: Biograph 64 Vision 450; Biograph mCT Flow; Biograph Truepoint
- 1 PET/MR Scanner: Biograph mMR
- 3 SPECT/CT scanners: all Symbia T
- 5 additional nuclear cameras
- Full Molecular Imaging and Therapy clinic with 3 lead lined therapy rooms, radiopharmacy, and office space
- The fellow will be compensated at the appropriate PGY salary level.
- Benefits include medical/vision/dental insurance, professional liability coverage, disability coverage, and paid time off.
- The fellow will attend an annual PET/CT and Molecular Imaging and Therapy course.
- Travel accommodations and reimbursements are granted for the fellow to attend the annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference and the Radiological Society of North America (RSNA) conference.
- If a fellow’s research project is accepted for presentation at a major radiology or molecular imaging meeting, the research fund will cover reasonable expenses and time to attend will be granted after coordination with and approval by the program director.
- There is one (1) position available for the 2025-2026 fellowship year. Current CA Medical License required. Applications accepted on a rolling basis.
- There is one (1) position available for the 2026-2027 fellowship year.
- 1 year (July 1, 2025 – June 30, 2026)
- 1 year (July 1, 2026 – June 30, 2027)
Candidate Qualifications
- Applicants must have completed a nuclear medicine or diagnostic radiology residency at an ACMGE accredited program and be either board-eligible or board-certified by the American Board of Nuclear Medicine or The American Board of Radiology. Applicants must be eligible to obtain an unrestricted California medical license prior to the beginning of the Fellowship. We are unable to provide J-1 visa sponsorship at this time.
- View the requirements for a California medical license
How to Apply?
- Candidates will be selected based on their clinical and imaging training, research experience, and letters of recommendation.
- Hoag’s Molecular Imaging & Therapy fellowship follows the SCARD interview embargo program for recruitment for Radiology Sub-Specialties that do not participate in the Match.
- Email your application documentation to: GMEOffice@hoag.org
Application Materials
- Application Form
- Curriculum Vitae: Please include honors, award, & publications on your curriculum vitae
- A personal statement that describes your: reasons for interest in molecular imaging training, training expectations, and practice expectations. Do not exceed one page in length, single spaced, with one-inch margins.
- Three (3) letters of recommendation – one letter must be from your residency Program Director
- Copies of:
- USMLE/COMLEX Score Reports
- Medical School Diploma
- ECFMG certificate if applicable
TBA
Faculty
Gary A. Ulaner, MD
James & Pamela Muzzy Endowed Chair in Molecular Imaging and Therapy; Director, Molecular Imaging and Therapy
Peter D. Giuliano, MD
<p>Dr. Peter Giuliano joined NHRA in 2003 and is the Director of the Department of Nuclear Medicine at Hoag.</p>
Ryan P. Reddy, MD
Diagnostic Radiology, Nuclear Medicine